Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy

• Published in: AIDS (London) Vol. 14; no. 1; p. 23
• Main Authors: Andreoni, M, Parisi, S G, Sarmati, L, Nicastri, E, Ercoli, L, Mancino, G, Sotgiu, G, Mannazzu, M, Trevenzoli, M, Tridente, G, Concia, E, Aceti, A
• Format: Journal Article
• Language: English
• Published: England 07.01.2000
• Subjects: Adult; Anti-HIV Agents - therapeutic use; CD4 Lymphocyte Count; Didanosine - therapeutic use; DNA, Viral - blood; Drug Therapy, Combination; Female; HIV Infections - drug therapy; HIV Protease Inhibitors - therapeutic use; HIV-1 - growth & development; HIV-1 - metabolism; Humans; Indinavir - therapeutic use; Male; Middle Aged; Prospective Studies; Proviruses - growth & development; Proviruses - metabolism; Reverse Transcriptase Inhibitors - therapeutic use; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral - blood; Stavudine - therapeutic use; Viremia - drug therapy
• ISSN: 0269-9370
• DOI: 10.1097/00002030-200001070-00003

To evaluate the decay rate of cellular proviral HIV-DNA and viral replication in patients receiving highly active antiretroviral therapy (HAART) in the very early phase of infection. Thirty-four patients treated with HAART and retrospectively selected for progressive decline of plasma viraemia up to undetectable levels (< 20 copies/ml), were stratified according to CD4+ cell count and plasma viraemia at base line: > 500 x 10(6) cells/l with < 5000 copies/ml (group 1) or with > 5000 copies/ml (group 2), > 5000 copies/ml with 300-500 x 10(6) cells/l (group 3) or with < 300 x 10(6) cells/l (group 4). Plasma HIV-RNA and proviral HIV-DNA were analysed at baseline and after 1, 2, 3, 6, 9 and 12 months of treatment. After 1 year of treatment, a significant decrease of proviral DNA titre was observed in all patients and a decrease > 1 log was achieved in 24 of 29 subjects of the first three groups. The more pronounced decay of HIV-DNA (half-life 28 weeks) up to < 50 HIV-DNA copies/10(6) CD4+ cells was detected in patients of group 1. At the year's endpoint, five patients (four in group 1 and one in group 2) had < 20 HIV-DNA copies. However, HIV strains sensitive to antiretroviral drugs were isolated from peripheral lymphocytes of 16 out of 34 patients. In patients with undetectable plasma viraemia after 1 year of HAART, the highest reduction of proviral DNA up to < 50 copies/10(6) CD4+ cells was obtained only in subjects in the early asymptomatic phase of infection. Nevertheless, a replication-competent virus can be detected in all phases of antiretroviral therapy.